Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com
A11504 | Pages: NA | Charts: NA | Tables: NA |
Osteoporosis disease is the most established disease that occurs due to less bone mineral density, which causes heavy risk of fractures and bone fragility. The disease occurs mostly in spine, hip, shoulder and forearm. Hip fractures are most common as nearly one-third of patients lose mobility and need long-term nursing. Furthermore, patients are unable to move, prolonged complications arising out of bed immobilization ultimately results into fatality. The diagnostic measures of osteoporosis include X-ray and radiography tests that are further acknowledged with bone density test. Moreover, the treatment of osteoporosis includes drugs such as Bio phosphates as alendronate, risedronate, Ibandronate and others. The Raloxifene drugs act as estrogen in females and thus, can be used in the treatment of osteoporosis in females. Furthermore, teriparatide is also a powerful drug that stimulates the new bone growth. The mode action of the drugs is mainly anabolic which affect not only bone remodeling but also in the healing the fracture. The human monoclonal antibody to RANKL is an anabolic drug to show the healing action in the animal model. Denosumab is the example of such drug showing the healing activity. There are studies going on still to find the potential effect on the anti-osteoporosis drugs on the action of the fracture healing.
COVID-19 Scenario analysis:
The COVID-19 pandemic has impacted the world as it made the population to face the lockdown. This led to the slow-down of the healthcare sectors and hospitals. The pandemic resulted in the decrease in growth of the market. Many patients faced the problems to consult hospitals for the treatment. This situation also impacted the market in the positive way by making the opportunities for new innovations in the anti-osteoporosis therapy and also fracture healing.
The increase in the prevalence of diseases like osteoporosis and surge in the number of the patients of this disease is expected to increase the growth of the market. The geriatric population is the main focus point for market players. Some of the other bone diseases are also contributing to increase in the growth of the market. Moreover, the increase in the expenditure of the research and development activities regarding the generation of the drugs is another factor responsible for the increase in the growth of the market. Also, the increase in the spread of the awareness about the osteoporosis diagnosis and treatment adds up to the growth of the market. Furthermore, increase in number of healthcare sectors like the trauma centers infrastructure, also leads to increase in the growth of the anti-osteoporosis therapy and fracture healing market.
However, the cases of complications seen while the treatment of the disease is in progress like the ulcers, irritable bowel syndrome and nausea are expected to hamper the growth of the market.
In September 2018, the U.S. Food and Drug Administration approved the launch of Risedronate Sodium Delayed release tablet in America. This drug was launched by Zydus Pharma Inc. It is used in the treatment of osteoporosis in postmenopausal women.
In April 2018, the Denosumab drug was approved by the Committee for Medicinal Products for Human use (CHMP) of the European Medicines Agency, for the company named Amgen, Inc. This drug is used to treat bone loss associated with prolonged systemic glucocorticoid therapy.
The increase in the incidences of the diseases like osteoporosis and other bone diseases lead to increase in the usage of the drugs. Moreover, the increase in the number of trauma centers at various places like remote areas can also help to surge the usage of the anti-osteoporosis therapy drugs.
Key benefits of the report:
Questions answered in the anti-osteoporosis therapy and fracture healing market research report:
Key Market Segments
Key Market Players